Americans traveling to Europe routinely purchase sunscreens that offer better protection than what's available at home, creating an ironic situation where tourists access safer products abroad that remain unavailable domestically. The regulatory divide stems from fundamentally different approaches: the FDA treats sunscreens as over-the-counter drugs requiring extensive approval processes, while the European Union classifies them as cosmetics with streamlined ingredient access.

This regulatory difference has real health consequences. European formulations can incorporate a wider range of active ingredients, providing superior defense against UVA rays—the more dangerous ultraviolet radiation that penetrates deeply and causes melanoma. Many American sunscreens would actually fail European UVA protection standards, making them better at preventing sunburn than skin cancer. The same pattern emerged during the pandemic when Europe approved rapid-antigen tests faster, potentially costing over 100,000 lives in delayed detection.

The proposed solution involves a peer-approval system that fast-tracks medications and devices already validated by stringent regulators like the European Medicines Agency. This approach has rare bipartisan backing, with support from figures as politically diverse as Sen. Ted Cruz and Rep. Alexandria Ocasio-Cortez. Similar recognition already exists in food regulation between the FDA and Canadian authorities.

Americans shouldn't need to travel abroad to access safer sunscreen or effective cold medicine like ambroxol, which has been used globally since 1979. The current system prioritizes bureaucratic caution over public health outcomes, demonstrating how excessive precaution can actually increase risk rather than reduce it.